Ticker > Company >

Norris Medicines share price

Norris Medicines Ltd.

BSE: 524414 SECTOR: Pharmaceuticals & Drugs  8.1 K   5   1

14.52
-0.48 (-3.20%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 15.75

Today's Low

₹ 14.5

52 Week High

₹ 24.65

52 Week Low

₹ 14.78

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

14.52 Cr.

Enterprise Value

36.06 Cr.

No. of Shares

1 Cr.

P/E

0

P/B

0

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  -15.82

CASH

0.04 Cr.

DEBT

21.58 Cr.

Promoter Holding

34 %

EPS (TTM)

₹  -1.54

Sales Growth

3.27%

ROE

0 %

ROCE

-10.11%

Profit Growth

-4.28 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year3.27%
3 Year-14.88%
5 Year-5.79%

Profit Growth

1 Year-4.28%
3 Year17.47%
5 Year9.36%

ROE%

1 Year0%
3 Year0%
5 Year0%

ROCE %

1 Year-10.11%
3 Year-5.19%
5 Year-8.01%

Debt/Equity

-1.4515

Price to Cash Flow

28.47

Interest Cover Ratio

-1.68

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2025 34.00 0.00
Jun 2025 34.00 0.00
Mar 2025 34.00 0.00
Dec 2024 34.00 0.00
Sep 2024 34.01 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

 Looks like the company does not have any notable strengths.

 Limitations

  • The company has shown a poor revenue growth of -14.8836954535703% for the Past 3 years.
  • Company has a poor ROE of 0% over the past 3 years.
  • Company has a poor ROCE of -5.1923% over the past 3 years
  • The company has a low EBITDA margin of -2.35244461241105% over the past 5 years.
  • The company has negative book value.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
Net Sales 1.27 1.11 2.72 1.46 2
Total Expenditure 1.41 1.13 2.65 1.56 2.49
Operating Profit -0.15 -0.03 0.07 -0.1 -0.49
Other Income 0 0 0.05 0.02 0
Interest 0.09 0.13 0.15 0.11 0.11
Depreciation 0.13 0.13 0.14 0.12 0.12
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.36 -0.28 -0.17 -0.31 -0.72
Tax 0 0 0.06 0 0
Profit After Tax -0.36 -0.28 -0.23 -0.31 -0.72
Adjusted EPS (Rs) -0.36 -0.28 -0.23 -0.31 -0.72

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 12.25 9.44 8.36 5.64 5.82
Total Expenditure 14 9.51 7.44 5.82 6.08
Operating Profit -1.74 -0.07 0.92 -0.18 -0.26
Other Income 0.05 0.03 0.01 0.03 0.06
Interest 1.63 1.48 1.5 0.37 0.44
Depreciation 0.67 0.66 0.63 0.57 0.54
Exceptional Items 0 0 0 0 0
Profit Before Tax -3.99 -2.18 -1.19 -1.1 -1.18
Tax 0.97 1.08 0.56 0.09 0.06
Net Profit -4.96 -3.26 -1.75 -1.19 -1.24
Adjusted EPS (Rs.) -5 -3.29 -1.76 -1.2 -1.25

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 9.93 9.93 9.93 9.93 9.93
Total Reserves -17.36 -20.62 -22.37 -23.56 -24.79
Borrowings 15.52 18.1 18.43 18.59 18.53
Other N/C liabilities -2.69 -1.61 -1.05 -0.96 -0.9
Current liabilities 11.69 6.78 7.7 9.23 10.15
Total Liabilities 17.1 12.58 12.63 13.22 12.91
Assets
Net Block 7.67 7.07 6.47 5.79 5.27
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.01 0.01 0.01 0.01 0.01
Loans & Advances 1.19 1.23 1.23 1.29 1.29
Other N/C Assets 0 0 0 0 0
Current Assets 8.23 4.27 4.92 6.14 6.34
Total Assets 17.1 12.58 12.63 13.22 12.91
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations -3.99 -2.18 -1.19 -1.1 -1.18
Adjustment 2.29 2.13 2.12 0.95 0.96
Changes in Assets & Liabilities 2.82 -0.95 0.27 0.32 0.73
Tax Paid 0 0 0 0 0
Operating Cash Flow 1.11 -1.01 1.2 0.17 0.51
Investing Cash Flow -0.06 -0.09 -0.02 0.05 0
Financing Cash Flow -1.09 1.1 -1.18 -0.2 -0.5
Net Cash Flow -0.04 0 0 0.02 0

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
promoters 34.01 34.00 34.00 34.00 34.00
dhirendra kantilal shah h... 0.34 0.34 0.34 0.34 0.34
milind l upadhyaya 0.01 0.01 0.01 0.01 0.01
navnit jethabhai patel 0.04 0.04 0.04 0.04 0.04
navsarjan investment & tr... 10.00 10.00 10.00 10.00 10.00
vimal d shah 23.60 23.60 23.60 23.60 23.60
nimish bhishma thakore 0.01 - - - -
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025% Sep 2025%
investors 65.99 66.00 66.00 66.00 66.00
fab metals private limite... 41.99 41.99 41.99 41.99 41.99
lkp securities limited 1.50 1.50 1.50 1.50 1.50

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Norris Medicines - Quaterly Results 14 Aug, 7:55 PM Norris Medicines - Quaterly Results 28 May, 6:05 PM Norris Medicines informs about outcome of board meeting 14 Feb, 2:40 PM Norris Medicines - Quaterly Results 13 Feb, 9:31 PM Norris Medicines informs about newspaper publication 10 Sep, 4:39 PM Norris Medicines - Quaterly Results 14 Aug, 4:53 PM Norris Medicines informs about change in management 3 Jul, 1:07 PM Norris Medicines informs about outcome of directors meeting 22 Mar, 5:24 PM Norris Medicines - Quaterly Results 14 Feb, 3:40 PM Norris Medicines - Quaterly Results 14 Feb, 3:40 PM Norris Medicines informs about closure of trading window 29 Sep, 4:55 PM Norris Medicines - Quaterly Results 10 Aug, 4:40 PM Norris Medicines - Quaterly Results 10 Aug, 4:40 PM Norris Medicines informs about issuance of duplicate share certificate 14 Jun, 4:55 PM Norris Medicines - Quaterly Results 25 May, 3:37 PM Norris Medicines - Quaterly Results 25 May, 3:37 PM Norris Medicines - Quaterly Results 25 May, 3:37 PM Norris Medicines informs about outcome of board meeting 13 Feb, 4:38 PM Norris Medicines - Quaterly Results 13 Feb, 12:39 PM Norris Medicines - Quaterly Results 13 Feb, 12:39 PM Norris Medicines - Quaterly Results 13 Feb, 12:39 PM Norris Medicines informs about unaudited financial results 11 Nov, 5:14 PM Norris Medicines - Quaterly Results 11 Nov, 11:25 AM Norris Medicines informs about outcome of board meeting 15 Sep, 5:13 PM Norris Medicines - Quaterly Results 27 Aug, 5:27 PM Norris Medicines - Quaterly Results 27 Aug, 5:27 PM Norris Medicines - Quaterly Results 27 Aug, 5:27 PM Norris Medicines - Quaterly Results 25 May, 2:54 PM Norris Medicines - Quaterly Results 25 May, 2:54 PM Norris Medicines - Quaterly Results 25 May, 2:54 PM Norris Medicines informs about PCS certificate 20 Apr, 4:48 PM Norris Medicines informs about compliance certificate 5 Apr, 5:02 PM Norris Medicines - Quaterly Results 12 Feb, 1:50 PM Norris Medicines informs about trading window closure 31 Dec, 3:49 PM Norris Medicines informs about book closure 28 Aug, 2:38 PM Norris Medicines informs about notice of 30th AGM 28 Aug, 12:59 PM Norris Medicines informs about compliance certificate 5 Jul, 12:50 PM Norris Medicines informs about non-applicability of annual secretarial compliance report 28 Jun, 4:25 PM Norris Medicines informs about board meeting 19 Jun, 11:35 AM Norris Medicines informs about demise of independent director 24 May, 12:34 PM Norris Medicines submits certificate 20 Apr, 3:30 PM Norris Medicines informs about compliance certificate 3 Oct, 3:47 PM Norris Medicines submits voting result of AGM 26 Sep, 3:53 PM Norris Medicines informs about disclosure of material impact of covid-19 1 Jun, 3:52 PM

Norris Medicines Stock Price Analysis and Quick Research Report. Is Norris Medicines an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Norris Medicines. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Norris Medicines has a PE ratio of -9.42306444285807 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Norris Medicines has ROA of -9.4719% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Norris Medicines has a Current ratio of 0.6246.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Norris Medicines has a ROE of 0%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Norris Medicines has a Debt to Equity ratio of -1.4515 which means that the company has low proportion of debt in its capital.

  • Sales growth: Norris Medicines has reported revenue growth of 3.2746% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Norris Medicines for the current financial year is -4.51598230089926%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Norris Medicines is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Norris Medicines is Rs -1.5409. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Norris Medicines in Ticker for free. Also, one can get the intrinsic value of Norris Medicines by using Valuation Calculators, which are available with a Finology ONE subscription. 

Norris Medicines FAQs

Q1. What is Norris Medicines share price today?
Ans: The current share price of Norris Medicines is Rs 14.52.

Q2. What is the market capitalisation of Norris Medicines?
Ans: Norris Medicines has a market capitalisation of Rs 14.5210164 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Norris Medicines?
Ans: The PE ratio of Norris Medicines is -9.42306444285807 and the P/B ratio of Norris Medicines is -0.917744320982972, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Norris Medicines share?
Ans: The 52-week high share price of Norris Medicines is Rs 24.65, and the 52-week low share price of Norris Medicines is Rs 14.78.

Q5. Does Norris Medicines pay dividends?
Ans: Currently, Norris Medicines does not pay dividends. Dividend yield of Norris Medicines is around 0%.

Q6. What are the face value and book value of Norris Medicines shares?
Ans: The face value of Norris Medicines shares is Rs 10, while the book value per share of Norris Medicines is around Rs -15.8214. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Norris Medicines?
Ans: Norris Medicines has a total debt of Rs 21.5804608 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Norris Medicines?
Ans: The ROE of Norris Medicines is 0% and ROCE of Norris Medicines is -10.1117%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Norris Medicines a good buy for the long term?
Ans: The Norris Medicines long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Norris Medicines undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Norris Medicines appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Norris Medicines’s financials?
Ans: You can review Norris Medicines’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Norris Medicines
X